| Octreotide is a safe adjunct therapy for the treatment of chylothorax and chylous ascites in neonates. |
| The efficacy of octreotide therapy and final outcome are affected by underlying genetic conditions and associated co-morbidities. |
| Early initiation of octreotide therapy can be considered in the management of chylothorax and chylous ascites. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.